Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. ... as Zaltrap has given way to Libtayo, their treatment for metastatic melanoma.

Regeneron is buying 23andMe’s consumer genetic-testing business, and says it plans to keep selling DNA tests to consumers. It’s also buying the 23andMe “Biobank,” a database of genetic ...

Regeneron's bid to purchase 23andMe, ... while furthering Regeneron’s efforts to use large-scale genetics research to improve the way society treats and prevents illness overall. ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Regeneron Pharmaceuticals is a ... With several promising label expansion projects under way, analysts predict that this powerful immunology drug could reach $20 billion in annual sales by 2030.

Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.

Regeneron Pharmaceuticals, a company that has been analyzing genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the ...

DNA testing company 23andMe is being purchased out of bankruptcy by large-cap drugmaker Regeneron for $256 million.The deal includes "substantially all assets" but excludes the telehealth platform ...

After a seven-day trial, jurors sided with Regeneron on 10 of 11 claims, and awarded $135.6 million in compensatory damages—the top end of what Regeneron’s expert suggested—and another $271. ...

Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...